I
Infinity Bio
Infinity Bio, Inc. is an antibody profiling company and developer of the up coming novel molecular display technology that employs self-assembling barcoded proteins and peptides
About Infinity Bio
Infinity Bio is a biotechnology company that has developed a proprietary platform for antibody reactome profiling, enabling the analysis of immune responses at a large scale. The company provides services to gain insights into the interactions between antibodies and antigens, particularly in the context of viral exposures and autoimmune diseases.
Its business model revolves around offering specialized services and analytics to researchers, pharmaceutical companies, and other entities in the life sciences sector. Infinity Bio generates revenue by providing access to its advanced technology and expertise in interpreting the complex data derived from antibody profiling. The company's key offerings include the VirSIGHT™ profiler, which focuses on the human virome, and the HuSIGHT™ profiler, which is geared towards understanding autoimmune responses. Additionally, Infinity Bio offers the creation of custom antigen libraries to meet specific research needs.
Source: Dealroom company dataAt a glance
- Founded
- 2023
- Headquarters
- Baltimore, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Blackbird Ventures
PTX Capital
Illumina Ventures- PFPropel Baltimore Fund
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Infinity Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Infinity Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.